Fuda Cancer Hospital
Rectal cancer treatment cost in China typically includes essential imaging like a PET-CT scan alongside surgical options. A rectal resection ranges from $18,200 to $34,500, while a laparoscopic mesorectumrctonomy runs from $18,500 to $31,500. Total expenses depend on the cancer stage and hospital tier, with patients often saving 40-60% compared to the US. Top cities for this treatment include Beijing, Shanghai, and Guangzhou.
Typical Rectal Cancer Treatment Costs in China
Bookimed Expert Insight: For patients with advanced or late-stage cancer, Fuda Cancer Hospital offers specialized minimally invasive therapies. They utilize NanoKnife and cryosurgery technologies to treat cases where traditional chemotherapy may not be ideal. This JCI-accredited facility has served over 30,000 international patients. For complex radiation needs, specialists like Dr. Liu Shi Xin at Xiamen Humanity Hospital provide advanced IMRT and SBRT protocols.
| China | Turkey | Austria | |
| Tomotherapy | from $17,500 | from $12,000 | from $30,000 |
| Rectal resection | from $18,200 | from $9,225 | from $21,000 |
| NanoKnife | from $22,500 | from $9,500 | from $25,000 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $22,500 | from $6,500 | from $40,000 |
| Gastric polyps removal | from $1,800 | from $752 | from $5,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Rectal cancer treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Rectal cancer treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Rectal cancer treatment journey.
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Professor Zheng Qiu Hong is Director of the Cell Therapy Research Center and a National Senior Expert in Biotherapy. He is a Professor and Master’s Supervisor at Fujian Medical University. He has more than 30 years of clinical experience in tumor molecular biology and biotherapy. From 2012 to 2013, he was a visiting scholar in stem cell research at the University of Connecticut School of Life Sciences. He previously held leadership roles at Fujian Cancer Hospital. These roles included Director of the Tumor Molecular Biology Laboratory and Director of the Surgical Oncology Research Laboratory. He also served as Deputy Director of the Fujian Key Laboratory of Tumor Biotherapy and Deputy Director of the Biotherapy and Immunotherapy Center.
Appointments include Standing Committee Member of the Biotherapy Committee of the Chinese Research Hospital Association. He is also a Committee Member of the Tumor Immunology and Biotherapy Committee of the Chinese Society for Immunology. In addition, he is Deputy Chair of the Academic Committee of the Xiamen Cell Therapy Research Center at the First Affiliated Hospital of Xiamen University.
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
Rectal cancer treatment in China centers on total mesorectal excision (TME) and minimally invasive surgeries. Top oncology hospitals in Guangzhou and Shanghai utilize the da Vinci robotic system. Specialized centers integrate cryosurgery, NanoKnife, and immunotherapy for advanced cases within JCI-accredited facilities.
Bookimed Expert Insight: Patient data shows a preference for Guangzhou-based centers due to their expertise in non-traditional therapies. Fuda Cancer Hospital has served over 30,000 international patients. They specialize in combining minimally invasive methods like NanoKnife with standard oncology protocols. This approach provides options for cases where conventional surgery is not the primary choice.
Patient Consensus: Patients emphasize verifying tumor genetics like MSI and KRAS early to access targeted drugs. Many note that treatment starts much faster in China than in Western countries.
Rectal cancer patients in China can avoid a permanent colostomy bag through advanced sphincter-preserving surgeries like Intersphincteric Resection (ISR). Major centers report that 75% of low rectal cancer cases now undergo successful anal preservation. Techniques like Neoadjuvant therapy shrink tumors to ensure safer removal while maintaining natural bowel function.
Bookimed Expert Insight: Clinical data indicates that elite JCI-accredited facilities like Fuda Cancer Hospital utilize over 10 types of minimally invasive therapies. Patients often overlook that while surgery is standard, combining it with local treatments like Cryosurgery or NanoKnife can improve margins. This multimodal approach specifically helps in preserving the sphincter for tumors located very close to the anal verge.
Patient Consensus: Patients emphasize the importance of seeking second opinions at tier-1 hospitals to avoid rushed permanent colostomies recommended by local clinics. They note that while an ileostomy may be necessary, it is typically temporary for 6 to 16 weeks during healing.
Robotic surgery for rectal cancer is highly accessible in Chinas top-tier tertiary hospitals. It accounts for nearly 49% of rectal procedures as of 2020. Major centers in Guangzhou, Shanghai, and Beijing utilize the da Vinci system and domestic platforms like MicroPort Toumai for precise tumor removal.
Bookimed Expert Insight: While elite centers like Fuda Cancer Hospital focus on minimally invasive cryosurgery and NanoKnife, robotic platforms are concentrated in large academic hospitals. Data shows these tertiary centers perform thousands of cases. This confirms high surgical proficiency in complex pelvic resections.
Patient Consensus: Patients note that robotic surgery significantly shortens hospital stays compared to open procedures. Many emphasize that traveling to major cities like Guangzhou is necessary to access this technology.
Rectal cancer patients in China access innovative immunotherapy drugs like Sintilimab, Toripalimab, and Pembrolizumab. Leading targeted therapies include Fruquintinib and Cetuximab. These medications target specific molecular markers such as MSI-H/dMMR or RAS wild-type. Facilities like Fuda Cancer Hospital provide advanced minimally invasive options alongside these pharmacological treatments.
Bookimed Expert Insight: While global drugs like Pembrolizumab are available, local innovations like Fruquintinib offer a significant advantage. Data from JCI-accredited facilities like Fuda Cancer Hospital shows they often combine these drugs with cryosurgery. This multi-modal approach serves over 30,000 international patients. Clinical packages for advanced radiation, like CyberKnife at Jinshazhou Hospital, may cost approximately 56,000 CNY (around $7,750). These local options often provide faster access than waiting for international trial spots in Tier-1 cities.
Patient Consensus: Patients emphasize getting MSI and PD-L1 testing early to unlock drug options. Many note that Fruquintinib is an effective third-line choice and more affordable than imported alternatives.
Integrating Traditional Chinese Medicine with Western rectal cancer treatment is generally safe under professional supervision. Leading Chinese centers like Fuda Cancer Hospital use integrated protocols to reduce chemotherapy side effects. Coordinated care helps manage nausea, protects immune function, and improves 5-year survival rates.
Bookimed Expert Insight: Patients seeking integrated care should prioritize hospitals affiliated with major universities. For example, Jinshazhou Hospital is part of the Guangzhou University of Chinese Medicine. This connection ensures TCM protocols are vetted by academic tumor boards. Packages here, like CyberKnife radiosurgery for approximately $7,850, focus on high-tech Western precision. This confirms that TCM is treated as a supportive specialty rather than a primary replacement.
Patient Consensus: Patients emphasize using TCM only for symptom relief after clearing specific herbs with their Western oncologist. Many note that tracking bloodwork rigorously is essential to catch any rare herb-induced kidney stress early.